Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Am J Cardiol ; 108(9): 1289-96, 2011 Nov 01.
Article in English | MEDLINE | ID: mdl-22000627

ABSTRACT

The aims of the present study were to estimate the prevalence of heart failure (HF) with preserved ejection fraction (HF-PEF) in patients with HF and to compare their clinical characteristics with those with reduced ejection fraction in non-Western countries. The left ventricular ejection fraction ≥ 45% if measured < 1 year before the visit was used to qualify the patients as having HF-PEF. Of the 2,536 consecutive outpatients with HF, 1990 (79%) had the EF values recorded. Of these patients, 1291 had HF-PEF, leading to an overall prevalence of 65% (95% confidence interval 63% to 67%). Compared to the patients with HF and a reduced ejection fraction, those with HF-PEF were more likely to be older (65 vs 62 years, p < 0.001), female (50% vs 28%, p < 0.001), and obese (39% vs 27%, p < 0.001). They more frequently had a history of hypertension (78% vs 53%, p < 0.001) and atrial fibrillation (29% vs 24%, p = 0.03) and less frequently had a history of myocardial infarction (21% vs 44%, p < 0.001). Only 29% of patients with HF-PEF and hypertension had optimal blood pressure control. Left ventricular hypertrophy was less frequent in those with HF-PEF (58% vs 69%, p < 0.001). The prevalence of HF-PEF was lower in the Middle East (41%), where coronary artery disease was more often found than in Latin America (69%) and North Africa (75%), where the rate of hypertension was greater. In conclusion, in the present diverse non-Western study, HF-PEF represented almost 2/3 of all HF cases in outpatients. HF-PEF mostly affects older patients, women, and the obese. Hypertension was the most frequently associated risk factor, highlighting the need for optimal blood pressure control.


Subject(s)
Heart Failure/epidemiology , Stroke Volume , Adrenergic beta-Antagonists/therapeutic use , Africa, Northern/epidemiology , Age Distribution , Aged , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Atrial Fibrillation/epidemiology , Cardiomyopathies/epidemiology , Coronary Artery Disease/epidemiology , Cross-Sectional Studies , Diuretics/therapeutic use , Female , Heart Rate , Humans , Hypertension/epidemiology , Hypertrophy, Left Ventricular/epidemiology , Latin America/epidemiology , Male , Middle Aged , Middle East/epidemiology , Mineralocorticoid Receptor Antagonists , Myocardial Infarction/epidemiology , Obesity/epidemiology , Prevalence , Sex Distribution
SELECTION OF CITATIONS
SEARCH DETAIL